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Serum YKL-40 and assessment of severity of bronchial asthma in 
Egyptian children  
INTRODUCTION 
The impact of genetic factors on the pathogenesis 
of allergy and asthma is currently an area of intense 
investigation. Mammalian chitinases may 
contribute to the pathogenesis of type 2 helper 
immune responses1,2. YKL-40 is synthesized in 
neutrophil precursors at the myelocyte-
metamyelocyte stage; it is stored in the specific 
granules of neutrophils and released from fully 
activated cells3 as well as from macrophages, 
neutrophils, chondrocytes, vascular smooth muscle 
and cancer cells4.CHI3L1, the gene that encodes for 
a chitinase-like protein YKL-40, has recently been 
shown to be highly heritable and associated with 
susceptibility to asthma5. Hence, Chitinase-like 
protein YKL-40 (also known as human cartilage 
glycoprotein 39 [HCgp-39] and chitinase 3-like 1) 
appears recently, to be important, in the 
pathogenesis, prediction and follow-up of asthma. 
The objective of this study was to assess the 
role of YKL-40 measurement in evaluating 
bronchial asthma severity, compared to clinical 




This is a cross-sectional observational study. 
Study population: 
Thirty known asthmatic children were enrolled 
from   Pulmonology Clinic of Children's Hospital, 
Ain Shams University from October 2008 till May 
2009.  These Patients were divided into two groups 
according to the global initiative for asthma6, fifteen 
were mild to moderate persistent asthma and fifteen 
of them were severe persistent asthma. Another 
group of 15 healthy age and sex matched subjects 
was enrolled to represent the control.  
We excluded patients with rheumatoid arthritis, 
inflammatory bowel disease and diabetes mellitus 
who might have confounders for measured YKL-
40. 
Tools for Assessment of asthma severity:  
In order to fulfill our study objective, we used 
different tools for severity assessment.  
Original article 
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1. Clinical examination of patients was done 
targeting the assessment of severity of the 
current state of asthma by Pediatric Asthma 
Scoring (PAS)7. 
2. Pulmonary function tests were performed using 
spirometry and tidal breathing measurements. 
We considered a typical case of obstructive 
defect is present when we found normal forced 
vital capacity (FVC), reduced  forced expiratory 
volume in the first second (FEV1), and reduced 
forced expiratory flow more than 25-75% of the 
FVC with FEV1/FVC ratio <0.80. Normative 
values for FEV1 have been determined for 
children, based on height, gender, and ethnicity. 
The guidelines cut-off values of FEV1 <80% 
denote severe airway obstruction and <60% of 
predicted was associated with moderate airway 
obstruction6,8. 
3. YKL-40 was quantitatively measured in 
patients' sera by ELIZA method (Metra™ 
YKL-40 EIA Kit-QUIDEL CORPORATION). 
Serum was collected using standard 
venipuncture technique. Specimens were 
collected without anticoagulants and processed 
to avoid hemolysis. Sera were frozen at ≤ -20°C 
for safe storage. The test principle depends on; 
adding a known quantity of purified YKL-40 to 
serum samples with different levels of 
endogenous YKL-40. Measuring the optical 
density (at 405 nm) of the resulting mixture, 
with plotting the results on the representative 
standard curve, was done to calculate YKL-40 
concentration. YKL-40 assay results are 
expressed in ng/mL. The minimum detection 
limit of the YKL-40 assay was 20 ng /mL. 
 
Statistical analysis : 
Results of descriptive statistics were expressed as a 
fraction of the total population, mean ± SD and 
median (range). Continuous variables were 
compared using Student’s t-test if the variable was 
normally distributed or Mann Whitney test if the 
variable was not. The chi-square statistics was used 
for categorical variables. Spearman correlation test 
was used to rank different variables against patients' 
serum YKL-40 positively or inversely. ROC curve 
(receiver operator characteristic curve), was used 
for detection of the best cut off value, and validity 
of YKL-40 as both a diagnostic and prognostic 
biomarker of asthma. Results were considered 
statistically significant with a p <0.05.  
The data were coded, entered and processed on 
computer using statistical package for social 




Serum YKL-40 levels: 
Serum YKL-40 was significantly higher in both 
asthmatic groups (mean 72.3±27 ng/ml in mild to 
moderate asthmatics, and 151.7±42ng/ml in severe 
asthmatic children) compared to the controls (mean 
35.7ng/ml), (p<0.01 and 0.02 respectively). The 
best cut off value of YKL-40 for diagnosis and 
screening of asthma was 45 ng/ ml, with specificity 
72% and sensitivity of 89%, positive predictive 
value (PPV) of 92% and negative predictive value 
(NPV) of 67% and accuracy of 85%. 
Severe cases of persistent asthma showed 
highly significant increased  levels of serum YKL-
40 compared to the mild to moderate forms of 
asthma (mean 151.7 ng/ml and 72.3 ng/ml 
respectively ; p <0.01). 
 
YKL-40 and Assessment of asthma severity: 
1- YKL-40 and pediatric clinical scoring of asthma 
(PAS): correlation of serum YKL-40 and the PAS 
score showed significant positive correlation 
between PAS scores and YKL-40 levels with r = 
0.35 and p< 0.05 in both groups of patients (figure 
1). 
2- YKL-40 and pulmonary function tests: 
pulmonary function testing showed no significant 
difference between FEV1 levels in both groups of 
asthmatic patients. Serum YKL-40 was inversely 
correlated to FEV1. This correlation reached a 
significant level within the group of severe 
persistent asthma (r =-0.32, p<0.05) but 
insignificant levels within the group of mild to 
moderate asthma (r =-0.12, p>0.05). The best cutoff 
value of YKL-40 as a marker for severe asthma in 
this study was 90 ng/ml, with sensitivity of 86.7% 
and specificity of 81%, with PPV of 81% and NPP 
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n (%) 
10 (67%) 9 (60%) 8 (50%) 
PAS score 
0-4 (normal) 
5-7 (mild attack) 
8-11(moderate) 
















Serum YKL-40 (ng/ml) 
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r =0.35,  p<0.05 r =0.34,  p<0.05 
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Figure 1. The correlation between PAS and serum levels of YKL-40 in patients with mild to moderate 




Serum YKL-40 levels regulated by polymorphisms 
in the CHI3L1 (chitinase 3-like 1- proteins) gene. 
Regulatory SNPs in CHI3L1 were associated with 
asthma, atopy, and immune-mediated diseases. This 
gene represents a novel asthma susceptibility gene. 
Variations in CHI3L1 have been associated with 
asthma risk and progression9. We tried in this study 
to answer the question of whether measuring serum 
YKL-40 can be useful in the diagnosis of asthma 
and assessment of its severity, so can replace a 
more sophisticated diagnostic and prognostic tool 
like PFT in our country. We found a significant 
increase in serum YKL-40 in asthmatic patients; 
this can be explained by the release of IL-13 from 
Th2 cells in the initial phases of asthma, which 
potently and selectively induces the expression of 
chitinase in airway epithelial cells and alveolar 
macrophages. Chitinase expression in epithelial 
cells stimulates the release of macrophage 
inflammatory protein (MIP)-1 which especially 
recruits monocytes, eotaxin and eotaxin-2 which 
specifically recruit eosinophils, and neutrophils into 
the airways resulting in airway inflammation and 
directly evoke smooth muscle contraction 
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manifested as airway hyper-responsiveness and 
asthma5.  
Chupp et al.1 quantified serum YKL-40 levels 
in three cohorts of patients with asthma and showed 
that serum levels of YKL-40 were increased in 
patients with asthma (median, 97.7 ng/ml) 
compared with healthy persons.  Ober et al.10 
performed a genome-wide association study of 
serum YKL-40 levels in asthmatic patients and 
tested them for an association between an 
implicated Single-Nucleotide Polymorphism (SNP) 
in the promoter region of CHI3L1 gene and serum 
YKL-40 levels in asthma. They found that serum 
levels of YKL-40 were 15% higher in those with 
asthma than in controls. Similar to our finding 
presented follow-up data demonstrating 
significantly higher levels of YKL-40 in both serum 
and BAL fluid of asthmatic patients after they were 
challenged with various allergens11. 
Ober and Chupp9   performed a cross-sectional 
analysis of samples from an established cohort of 
asthmatic subjects and controls from the Yale 
Center for Asthma and Airways Disease and 
showed that YKL-40 levels were significantly 
higher in the serum of asthmatic subjects compared 
with non-asthmatic subjects. 
Serum YKL-40 was significantly higher in 
patients with severe asthma compared to those with 
mild to moderate asthma (best cut-off value was 90 
ng/ml). These levels were significantly positively 
correlated to the corresponding PAS score and the 
degree of airway obstruction by PFT.  
This is consistent with Basek et al.12 who 
showed that the value of commonly used 
pulmonary function tests in short- and long-term 
evaluations of childhood asthma remains 
controversial. They recommended that other 
parameters may be more valuable for this purpose. 
Moreover, there is a general finding that most 
asthmatic children have FEV1 values in the normal 
range. So if the diagnosis or the management of 
asthma greatly relies on FEV1 measurements, there 
will be a risk of under-diagnosing or under-treating 
asthmatic children13.  
Some researchers explain the significant rise of 
YKL-40 in severe asthmatics by the patho-
physiological role of YKL-40 in asthma as it is 
Th2- cytokine IL-13 dependent11. Shuhui et al.5 
revealed that YKL-40 might have a protective role 
to the lung through attenuating airway 
inflammation and airway hyper-responsiveness. 
Persistently elevated serum YKL-40 level was a 
significant marker of antigen-driven inflammation 
and remodeling in the asthmatic airway. 
Though the mechanism of this marked increase 
in severe asthmatics is not well known in the 
literature, yet YKL-40 was found in serum before 
and 24 hours after segmental allergen challenge in 
13 patients with allergic asthma, YKL-40 
concentrations were significantly elevated in serum 
before challenge (p = 0.01) and even more elevated 
(p = 0.003) 24 hours after allergen11. Moreover, 
serum YKL-40 levels were significantly correlated 
to the degree of alveolar membrane thickening in 
severe asthmatic patients after taking lung 
biopsies1. Ober et al.10 showed that serum YKL-40 
levels were inversely correlated with FEV1 (p = 
0.02) but not with forced vital capacity (FVC) (p = 
0.16), theFEV1: FVC ratio (p = 0.98), or forced 
expiratory flow between 25% and 75% of the FVC 
(FEF25–75) (p = 0.41). 
In conclusion, serum YKL-40 protein was 
found in increased quantities in asthmatic patients 
and these levels correlated positively with the 
severity of the disease. YKL-40 proved to be a 
simple and a novel useful biomarker for asthma 
severity assessment that can overcome the 
difficulties associated with PFTs in children. 
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